TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04591860

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic or robot-assisted hiatal closure (sutures only vs. absorbable mesh vs. pledgeted sutures) and fundoplication according to Toupet
Description: Patients are scheduled to undergo laparoscopic or robot-assisted surgery for a large symptomatic hiatal hernia.The hiatal closure will be done with sutures, pledgeted sutures or absorbable mesh (Phasix™ST mesh). After cruroplasty a fundoplication according to Toupet will be done additionally.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic or robot-assisted hiatal closure (sutures only vs. absorbable mesh vs. pledgeted sutures) and fundoplication according to Toupet
Description: Patients are scheduled to undergo laparoscopic or robot-assisted surgery for a large symptomatic hiatal hernia.The hiatal closure will be done with sutures, pledgeted sutures or absorbable mesh (Phasix™ST mesh). After cruroplasty a fundoplication according to Toupet will be done additionally.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic or robot-assisted hiatal closure (sutures only vs. absorbable mesh vs. pledgeted sutures) and fundoplication according to Toupet
Description: Patients are scheduled to undergo laparoscopic or robot-assisted surgery for a large symptomatic hiatal hernia.The hiatal closure will be done with sutures, pledgeted sutures or absorbable mesh (Phasix™ST mesh). After cruroplasty a fundoplication according to Toupet will be done additionally.
Study: NCT06040268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advair HFA
Description: 6 puffs (total: salmeterol 126 ug and fluticasone 270 ug) twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HFA134a inhaler
Study: NCT05272085

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Lavage
Description: After local anesthesia of subcutaneous tissue, lavage will be performed under the guidance of ultrasound using an 18-gauge needle with injectors filled with 4 ml of saline. The needle will be advanced to the center of the calcific deposit. The injector will be kept as parallel to the ground as possible. The plunger of the injector will be pushed with a gently pressure and then released. Calcific deposits are expected to be filled into the syringe along with saline. It is predicted that the clear saline will gradually turn white and become cloudy due to the incoming calcific deposits. When the color of the liquid becomes cloudy, the syringe will be removed without moving the needle, and a new syringe containing 4 ml saline will be placed in its place. Thus, the aspirated calcific deposits will not be reinjected. The same process will be repeated with a new saline filled syringe. After the procedure, 2 ml dexamethasone and 3 ml lidocaine will be injected in subacromial bursa.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Subacromial Bursa Injection
Description: 2 ml dexamethasone and 3 ml %2 lidocaine will be injected in the subacromial bursa using a 21-gauge needle under ultrasound guidance.
Study: NCT05504720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg flat dose, IV, over 30 minutes; day 1, 22, 43 (8 weeks) pre- and post-surgery, followed by post chemotherapy phase day 1 q3w for 11 cycles; max. 17 applications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: loading dose 8 mg/kg IV over 90 min: day 1 pre- and post-surgery; maintenance dose 6 mg/kg IV over 30 min: Day 22, 43 pre- and post-surgery; followed by 6 mg/kg post chemotherapy phase, day 1 q3w for 11 cycles; max. 17 applications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT
Description: Docetaxel 50 mg/m² IV over 1 hour plus Oxaliplatin 85 mg/m² IV over 2 hours plus Folinic Acid 200 mg/m² IV over 1 hour plus 5-FU 2600 mg/m² IV over 24 hours every 2 weeks (day 1, 15, 29, 43) for 8 weeks pre- and 8 weeks post-surgery
Study: NCT05011448

Intervention type: OTHER
Group type: OTHER
Intervention: Music Therapeutic Interaction and Verbal Interaction
Description: In both sessions (the Verbal Interaction and the Music Therapeutic Interaction) participants will be asked to perform three piano playing exercises in a fixed order: (1) playing a musical scale, (2) playing a short excerpt from a familiar song, and (3) free improvisation. Both sessions will also include a protocol of verbal instructions given by the therapist before each exercise. In session A ('Verbal Interaction') participants will perform these exercises alone while the therapist is only interacting with them verbally (asking them questions, commenting regarding their performance etc.). In session B ('Music Therapeutic Interaction') participants will perform these exercises while the therapist is interacting with them musically, using various music therapy techniques that are matched and attuned to each patient's playing dynamics and style. This is to reflect the dynamics of the music therapeutic interaction as it occurs in the real world of music therapy practice.
Study: NCT06520540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDM1002 100 mg QD 12weeks
Description: Participants received maintenance dose of 100 mg HDM1002 administered orally once daily (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDM1002 200 mg QD 12weeks
Description: Participants received maintenance dose of 200 mg HDM1002 administered orally once daily (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDM1002 200 mg QD 12weeks
Description: Participants received maintenance dose of 200 mg HDM1002 administered orally once daily (QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDM1002 400 mg QD 12weeks，Q 2W for titration
Description: Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDM1002 400 mg QD 12weeks，Q 2W for titration
Description: Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDM1002 400 mg QD 12weeks，Q 2W for titration
Description: Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 2W for titration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDM1002 400 mg QD 12weeks，Q 3W for titration
Description: Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDM1002 400 mg QD 12weeks，Q 3W for titration
Description: Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDM1002 400 mg QD 12weeks，Q 3W for titration
Description: Participants received maintenance dose of 400 mg HDM1002 administered orally once daily (QD) Q 3W for titration

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04988633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention CFG App
Description: Online healthy lifestyle education through an App. The intervention will consist of viewing educational videos on diet and exercise through an App. Videos will be uploaded to the app on a weekly basis, lasting 2-3.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Standard tips for healthy lifestyles that are carried out in regular Primary Care practice. After day 1, where standard advice is received, follow-up visits are conducted at week 2, week 4, month 3, and month 6.
Study: NCT06740071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pelvic floor magnetic stimulation therapy
Description: stimulation frequency was set at 10 Hz, with stimulation administered in cycles of 5 seconds on followed by 5 seconds off. Each treatment session lasted 20 minutes, conducted twice a week, for a total of 10-12 sessions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor magnetic stimulation therapy
Description: stimulation frequency was set at 10 Hz, with stimulation administered in cycles of 5 seconds on followed by 5 seconds off. Each treatment session lasted 20 minutes, conducted twice a week, for a total of 10-12 sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard pelvic floor muscle training
Description: traditional verbal instructions and paper-based educational materials of PFMT are given to participants.~All patients would receive PFMT under the guidance of digital rectal examination by nurses, and their pelvic floor muscle function was graded according to the Oxford Grading System (grades 0-5), ensuring the correctness of subsequent PFMT.
Study: NCT06114836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Omeprazole will be the PPI prescribed for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AR formula
Description: Added rice formula will be ordered for 4 weeks.
Study: NCT05848115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-level Positive Airway Pressure
Description: An appropriately sized vented BiPAP face mask with a good seal will be applied and monitored by trained respiratory therapists. Patients will be started on an inspiratory peak airway pressure (IPAP) of 10 cm of water and expiratory positive airway pressure (EPAP) of 5 cm of water per Children's Hospital Colorado (CHCO) clinical pathway. BiPAP pressures will be titrated to effect per the treating physician, using assessment of physical examination, vitals, and asthma score per institutional clinical pathway. Study participants will remain on BiPAP for four hours or until weaned off continuous beta-agonist therapy by the treating clinician. After the four-hour intervention period, it is at the discretion of the treating clinician regarding the ongoing use of BiPAP or not.
Study: NCT06740682

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Podcast olumlu doğum hikayeler
Description: ositive birth stories were listened to by women who gave birth in the hospital included in the study and created with their permission. The podcast recording was done in a single session. These positive birth stories were expertly reviewed by 3 obstetricians and 3 academics. Each podcast content is 10 to 20 minutes (Cai et al., 2023). A WhatsApp reminder msg will be sent so that the stories are not forgotten.~In addition, the pregnant woman will be contacted by phone and trained to listen (Cai et al., 2023).~Participants will be allowed to listen to the podcasts as much as they want (Cai et al., 2023). After listening to each story, their feedback will be received and the participants' doubts will be clarified. (Cai et al., 2023; Çankaya and Şimşek, 2021; Mousavi et al., 2022).~Based on multimedia principles, podcast positive birth experiences will be prepared (Clark and Mayer, 2023). Week 24, Week 30-32, Week 36-38 First story
Study: NCT06740604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BSD-10CH
Description: The BSD-10CH stimulation was applied five times a week for 4 weeks, with each session lasting 20 minutes per day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham BSD-10CH
Description: The Sham BSD-10CH stimulation was applied five times a week for 4 weeks, with each session lasting 20 minutes per day.
Study: NCT06739044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozempic®
Description: The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDG1901
Description: The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
Study: NCT06738446

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multicomponent dietary supplement group
Description: Participants in supplement group were asked to take a capsule content are eicosapentaenoic acid 45 mg, docosahexaenoic acid 30 mg, lutein 30 mg, and zeaxanthin1.8 mg every day for 12 weeks
Study: NCT05848115

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Bi-level Positive Airway Pressure
Description: The sham BiPAP will have pressure attenuated using an orifice restrictor as described in previous double blinded studies using sham non-invasive ventilation. With this set-up pressures no greater than 2 cm of water have been documented at the location of the face mask. This will ensure that the patient is not receiving positive pressure with any effectiveness or deleterious effects. Study participants will remain on sham BiPAP for four hours or until weaned off continuous beta-agonist therapy by the treating clinician. After the four-hour intervention period, it is at the discretion of the treating clinician regarding the use of BiPAP or not.
Study: NCT06741059

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transkutanöz Elektriksel Sinir Stimülasyonu - TENS
Description: Transcutaneous Electrical Nerve Stimulation (TENS) has gained popularity in recent years as a non-invasive method for pain management. TENS works by modulating nerve stimulation through low-frequency electrical currents applied to the skin, reducing pain perception. Its potential effectiveness in alleviating menstrual pain has drawn increasing attention as an alternative treatment option

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transkutanöz Elektriksel Sinir Stimülasyonu - TENS
Description: Transcutaneous Electrical Nerve Stimulation (TENS) has gained popularity in recent years as a non-invasive method for pain management. TENS works by modulating nerve stimulation through low-frequency electrical currents applied to the skin, reducing pain perception. Its potential effectiveness in alleviating menstrual pain has drawn increasing attention as an alternative treatment option
Study: NCT06736639

Intervention type: PROCEDURE
Intervention: Anchor Suture with Titanium Cable Cerclage
Description: This intervention involves the use of \*\*anchor suture fixation combined with titanium cable cerclage\*\* for the treatment of inferior pole patellar fractures (IPPF). The anchor suture provides stable fixation of fracture fragments by anchoring directly into the bone, while the titanium cable cerclage offers additional reinforcement around the patella to enhance stability and minimize fragment displacement. This method is specifically designed to address the limitations of traditional Kirschner-wire tension band techniques, such as hardware irritation and infection, by using biocompatible and low-profile materials.

Intervention type: PROCEDURE
Intervention: Kirschner wire tension band + cerclage cable
Description: This intervention uses \*\*Kirschner wire tension band combined with cerclage cable\*\* to treat inferior pole patellar fractures (IPPF). The Kirschner wires are positioned across the fracture site to form a tension band, which transforms tensile forces into compressive forces, promoting fracture stability. The cerclage cable is added to reinforce the fixation by encircling the patella, providing additional stability to comminuted or complex fractures.
Study: NCT06738199

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary iron supplementation
Description: This study aimed to compare the absorption kinetics of iron bound to a glycoprotein matrix (GPM) with those of ferrous bisglycinate chelate (FBC) and ferrous fumarate (FF).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary iron supplementation
Description: This study aimed to compare the absorption kinetics of iron bound to a glycoprotein matrix (GPM) with those of ferrous bisglycinate chelate (FBC) and ferrous fumarate (FF).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary iron supplementation
Description: This study aimed to compare the absorption kinetics of iron bound to a glycoprotein matrix (GPM) with those of ferrous bisglycinate chelate (FBC) and ferrous fumarate (FF).
Study: NCT06739850

Intervention type: COMBINATION_PRODUCT
Intervention: Identification of Risk Phenotypes of Sarcopenia
Description: Sarcopenia is a condition characterized by progressive loss of skeletal muscle mass, strength, and function, often associated with aging. Traditionally, it is studied in older populations, but your focus is on identifying its early manifestations in young adults, potentially offering a window for prevention.
Study: NCT05100212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cord blood-RBC concentrates
Description: Patients in the experimental arm are candidates to receive CB-RBC units until the completion of 31 weeks of postmenstrual age (31+6). In case of unavailability of an ABO/Rh matched CB-RBC unit, patients receive adult -RBC (standard transfusions).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adult donor RBC concentrates
Description: Patients in the comparator arm are candidates to receive adult donor-RBC units
Study: NCT03954483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone 10 Mg Oral Tablet
Description: Orally administered prior to experiments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 MG Oral Tablet
Description: Orally administered prior to experiments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Orally administered prior to experiments.
Study: NCT06396858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 2.5 Mg Oral Tablet
Description: Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Rivaroxaban
Description: Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Rivaroxaban
Description: Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Colchicine
Description: Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Colchicine
Description: Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.
Study: NCT05291234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-916
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-916
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-916
Description: Intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration
Study: NCT04703504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple intervention program
Description: Support for patient follow-up assisted by a computer program
Study: NCT05299463

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Exercise Testing
Description: * Tele-Six-minute walk test (T6MWT)~* 1 Minute Sit-to-stand test (STS)~* 2-minute symptom-limited Step test (ST)~* 3-metre Timed up and go test (TUG).
Study: NCT04382963

Intervention type: OTHER
Group type: OTHER
Intervention: High Risk - intensive coaching
Description: The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education, intensive coaching face-to-face.~Furthermore, this group will receive intensive initiation of the American Heart Association Guidelines for Management of Risk Factors with individual face-to-face coaching meetings on lifestyle change and adherence to treatment on at a least quarterly basis.

Intervention type: OTHER
Group type: OTHER
Intervention: High Risk - standard care
Description: The following assessment will occur: health assessment, blood pressure, BMI, history TIA/stroke, blood mRNA and protein analysis, ultrasound, cognitive assessment, stroke education.

Intervention type: OTHER
Group type: OTHER
Intervention: Low Risk - control
Description: Control participants will undergo the same study events as the Low Risk group, except without receiving information and advice about eliminating stroke risk factors.
Study: NCT05972759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forced and voluntary exercise
Description: Twenty-five participants with PD utilizing the Medtronic Percept PC DBS system will be enrolled for this project and complete a single bout of both FE and VE. The 150-minute experimental session will be completed in the OFF antiparkinsonian and Off-DBS state.
Study: NCT05836311

Intervention type: DEVICE
Intervention: One Perclose Proglide Suture
Description: One Perclose Proglide Suture

Intervention type: DEVICE
Intervention: Two Perclose Proglide Suture
Description: One Perclose Proglide Suture